Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

81. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery

Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery 21571492 2011 09 05 2011 11 10 2017 02 20 1097-6809 54 3 2011 Sep Journal of vascular surgery J. Vasc. Surg. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. 779-84 10.1016/j.jvs.2011.03.003 Persistent variation in practice surrounds preoperative clopidogrel management at the time of vascular surgery. While some surgeons preferentially discontinue (...) clopidogrel citing a perceived risk of perioperative bleeding, others will proceed with surgery in patients taking clopidogrel for an appropriate indication. The purpose of this study was to determine whether preoperative clopidogrel use was associated with significant bleeding complications during peripheral arterial surgery. We reviewed a prospective regional vascular surgery registry recorded by 66 surgeons from 15 centers in New England from 2003 to 2009. Preoperative clopidogrel use within 48 hours

EvidenceUpdates2011

82. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again

NIHR HTA programme2011

83. Clopidogrel for Cardiovascular Prevention (After Prior Heart Attack or Stroke)

Clopidogrel for Cardiovascular Prevention (After Prior Heart Attack or Stroke) Clopidogrel for Cardiovascular Prevention (After Prior Heart Attack or Stroke) – TheNNTTheNNT Clopidogrel to Prevent Cardiovascular Disease for People Who Have Had Heart Attacks or Strokes 50 for cardiac benefit In Summary, for those who took the clopidogrel daily for a year: Benefits in NNT 98% saw no benefit 1.3% were helped by preventing a non-fatal heart attack 0.5% were helped by preventing a non-fatal stroke (...) ) 1 in 91 were harmed (diarrhea, compared to aspirin usage) *Required hospital admission and transfusion View As: NNT % Source: Efficacy Endpoints: Heart attack, stroke, death Harm Endpoints: Bleeding, death Narrative: Clopidogrel blocks the action of platelets, reducing the chance of blood clots. Aspirin uses this same mechanism to reduce heart attacks, strokes, and deaths for patients with heart disease and strokes. Because aspirin is inexpensive, effective, and safe, clopidogrel is typically

theNNT2011

84. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial Results of the Continuous Electrocardiogra

The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial Results of the Continuous Electrocardiogra 21545948 2011 05 06 2011 07 05 2014 11 20 1558-3597 57 19 2011 May 10 Journal of the American College of Cardiology J. Am. Coll. Cardiol. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary (...) syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. 1908-16 10.1016/j.jacc.2010.11.056 The aim of this study was to determine whether ticagrelor increased the risk of ventricular pauses compared with clopidogrel and whether these pauses were associated with any clinical bradycardic events in patients presenting with acute coronary syndromes. Ticagrelor, an oral reversibly

EvidenceUpdates2011

85. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. 21252171 2011 04 04 2011 12 27 2016 12 15 1522-9645 32 7 2011 Apr European heart journal Eur. Heart J. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti (...) -Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. 838-46 10.1093/eurheartj/ehq494 Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater reductions in ischaemic events compared with clopidogrel, particularly in patients with DM. The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

86. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention

Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention 21247527 2011 03 07 2011 06 03 2015 11 19 1879-1913 107 6 2011 Mar 15 The American journal of cardiology Am. J. Cardiol. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. 871-8 10.1016/j.amjcard.2010.10.073 The aim of the present study was to analyze the effect of drug exposure patterns of clopidogrel and proton pump inhibitors (...) . The adjusted hazard ratio for MACE on PPI according to the exposure patterns of clopidogrel after PCI for 6 years was 1.24 (95% confidence interval [CI] 1.11 to 1.38) and 1.12 (95% CI 1.03 to 1.22) for "continuous" (consistent clopidogrel with or without PPIs) and "switched" (clopidogrel with or without varying PPIs) respectively. However, the propensity score adjusted odds ratios for MACE on PPI use was 0.97 (95% CI 0.65 to 1.44) for "continuous" and 1.04 (95% CI 0.87 to 1.25) for "switched." Moreover

EvidenceUpdates2011

87. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis

Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis 21144850 2011 03 07 2011 05 09 2016 11 25 1528-0012 140 3 2011 Mar Gastroenterology Gastroenterology Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. 791-8 10.1053/j.gastro.2010.11.056 We performed a prospective, randomized, controlled study to compare the combination of esomeprazole (...) and clopidogrel vs clopidogrel alone in preventing recurrent peptic ulcers in patients with atherosclerosis and a history of peptic ulcers. We also investigated the effects of esomeprazole on the antiplatelet action of clopidogrel. From January 2008 to January 2010, long-term clopidogrel users with histories of peptic ulcers who did not have peptic ulcers at an initial endoscopy examination were assigned randomly to receive the combination of esomeprazole (20 mg/day, before breakfast) and clopidogrel (75 mg

EvidenceUpdates2011

89. CYP2C19 Genotype and Outcomes of Clopidogrel Treatment.

CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. CYP2C19 genotype and outcomes of clopidogrel treatment. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21288101 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Feb 3;364(5):481-2. doi: 10.1056/NEJMc1013331#SA2. CYP2C19 genotype and outcomes of clopidogrel treatment. , , . Comment on [N Engl J Med. 2010] PMID: 21288101 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment

NEJM2011 Full Text: Link to full Text with Trip Pro

90. CYP2C19 Genotype and Outcomes of Clopidogrel Treatment.

CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. CYP2C19 genotype and outcomes of clopidogrel treatment. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21288102 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Feb 3;364(5):481; author reply 482. doi: 10.1056/NEJMc1013331#SA1. CYP2C19 genotype and outcomes of clopidogrel treatment. , , . Comment on [N Engl J Med. 2010] PMID: 21288102 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite

NEJM2011 Full Text: Link to full Text with Trip Pro

91. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial 20802246 2010 12 15 2011 12 07 2014 12 03 1522-9645 31 24 2010 Dec European heart journal Eur. Heart J. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. 3006-16 10.1093/eurheartj/ehq325 patients with diabetes mellitus (DM) have (...) high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control. we analysed patients

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

92. Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study)

Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study) 21146678 2010 12 14 2011 02 08 2013 11 21 1879-1913 107 1 2011 Jan The American journal of cardiology Am. J. Cardiol. Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective (...) percutaneous intervention (from the CADICE study). 6-9 10.1016/j.amjcard.2010.08.035 In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg). However, the applicability of these data to stable patients who undergo elective percutaneous coronary intervention is still unclear. A total of 400 patients who underwent elective PCI were prospectively randomized to receive

EvidenceUpdates2011

93. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic review and economic analysis

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic review and economic analysis Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic review and economic analysis Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic (...) applied. Authors' objectives To assess the effectiveness of clopidogrel or modified-release dipyridamole with or without aspirin, compared with aspirin alone or to each other, for the prevention of occlusive vascular events in people with a history of myocardial infarction, stroke or peripheral artery disease. Searching MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from 2003 to 2009. Manufacturer submissions to the National Institute of Health and Clinical Excellence were also

DARE.2011

94. Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarct

Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarct Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke (...) are here Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with … Article Text Therapeutics Randomised controlled trial Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk

Evidence-Based Medicine (Requires free registration)2011

95. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

EvidenceUpdates2011

96. Clopidogrel 150 vs 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis

Clopidogrel 150 vs 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis Clopidogrel 150 vs 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis Clopidogrel 150 vs 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis Hao PP, Zhang MX, Li RJ, Yang JM, Wang JL, Chen YG, Zhang Y CRD summary This review concluded that 150mg/day maintenance dose of clopidogrel for patients who underwent percutaneous (...) coronary intervention could reduce major adverse cardiac and/or cerebrovascular events, but could increase the risk of minor bleeding. This was a generally well conducted review and the conclusions are probably reliable. Authors' objectives To estimate the relative effect of 150mg versus 75mg daily maintenance dose of clopidogrel on clinical and laboratory endpoints in patients who underwent percutaneous coronary intervention. Searching Nine databases including MEDLINE, EMBASE, J-STAGE (Japan Science

DARE.2011

97. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after (...) percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S CRD summary Routine early tirofiban use plus aspirin and clopidogrel in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention may have reduced major adverse cardiovascular events without increasing major bleeding rates. The conclusions were not definitive due to limited

DARE.2011

98. Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel | Evidence-Based Medicine This site uses cookies (...) with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Article Text Prognosis Systematic review Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Andrea H Ramirez 1 , Jessica T Delaney 1 , Alan R Shuldiner 2 Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2011

99. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin

Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Xie X, McGregor M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Xie X (...) , McGregor M. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin. Montreal: Technology Assessment Unit of the McGill University Health Centre (MUHC). Report no. 53. 2011 Authors' conclusions • The applicant intends to use the VerifyNow test to detect those patients at increased risk of arterial thrombotic events due to Clopidogrel resistance. Patients found to be clopidogrel resistant will be treated with other thienopyridine drugs. • The VerifyNow test is easy

Health Technology Assessment (HTA) Database.2011

100. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies

Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies Nijjer SS, Watson G (...) , Athanasiou T, Malik IS CRD summary This review found that patients with acute coronary syndrome who required urgent coronary artery bypass graft surgery could proceed with surgery without a washout period delay to cease clopidogrel use. Methodological flaws mean the results should be interpreted with caution and the authors' conclusion is uncertain. Authors' objectives To determine the risk of mortality, reoperation, perioperative myocardial infarction, and stroke in patients with acute coronary syndrome

DARE.2011